13 Jan 2014, BioSpectrum Bureau , BioSpectrum
Singapore: Mr Jonathan M Peacock, executive vice president and chief financial officer of Amgen, is leaving the firm to pursue broader career opportunities. Mr Peacock will be stepping down from his role as CFO effective Friday, January 10, 2014, and is expected to remain employed with the company until May to assist with the transition.
Mr Michael A Kelly, an 11-year Amgen veteran, has been named acting CFO. He will report to Mr Robert A Bradway, chairman and chief executive officer (CEO).
In his role as acting CFO, Mr Kelly will be responsible for the company's finance and investor relations operations. Since joining Amgen in 2003, he has served in a number of executive finance assignments, including five years as chief accounting officer and more recently as CFO for international commercial operations. Prior to joining Amgen, Mr Kelly held finance roles at Tanox, Biogen and Monsanto.
Mr Bradway said, "Since joining Amgen over three years ago, Jon has played an important role in developing and implementing the company's strategy for growth and in delivering value for shareholders. We thank Jon for his many contributions and fully support his desire to pursue broader opportunities. Michael Kelly is an experienced financial executive. I am delighted to have him reporting to me as acting CFO while we search for Jon's successor."